RGRX (RGRX) Stock Price & Analysis
RGRX (RGRX) rose 0.00% to USD 0 as of June 10, 2026 at 03:29 UTC, according to Nexqual real-time market data.
RGRX last closed at USD 0; the session ranged USD 0.16–0.16 on volume of 252 shares. Market capitalization is $898, with a 52-week range of USD 0–0.16 (PNK). Source: Nexqual, June 10, 2026 at 03:29 UTC.
Key Statistics (as of June 10, 2026 at 03:29 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0.16 |
| Day Range | USD 0.16 – 0.16 |
| 52-Week Range | USD 0 – 0.16 |
| Volume | 252 shares |
| Market Cap | $898 |
| Exchange | PNK |
Technical Analysis (RGRX)
Nexqual's technical model rates RGRX "STRONG BUY" based on 6 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 03:29 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 0) |
| MACD | 0 (positive) |
Analyst Ratings (RGRX)
Wall Street analysts rate RGRX "None", per Nexqual as of June 10, 2026 at 03:29 UTC.
| Consensus Rating | None |
|---|
Earnings (RGRX)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2017-09-30 | USD -1 vs est 0 ▼ miss |
| 2017-06-30 | USD 0 vs est 0 ▲ beat |
| 2017-03-31 | USD 0 vs est 0 ▲ beat |
| 2016-12-31 | USD 0 vs est 0 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:29 UTC.
Financials & Fundamentals (RGRX)
| Total Revenue | $76,760 |
|---|---|
| Revenue Growth (YoY) | +0.00% |
| Gross Margin | +100.00% |
| Operating Margin | -1588.91% |
| Profit Margin | +0.00% |
| Current Ratio | 0.07 |
| Total Cash | $101,557 |
| Total Debt | $1.49M |
| Free Cash Flow | $-355,278 |
Source: Nexqual, June 10, 2026 at 03:29 UTC.
Financial Health Score (RGRX)
Nexqual rates RGRX's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:29 UTC.
| Growth | Strong — Revenue +54% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $102K cash vs $1M debt |
| Cash Flow | Weak — FCF negative: -$355K, burning cash |
| Efficiency | Mixed — No data |
Ownership (RGRX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 1.50M |
| Float | 1.09M |
| Short % of Float | +0.05% |
Source: Nexqual, June 10, 2026 at 03:29 UTC.
Leadership (RGRX)
RGRX is led by J. J. Finkelstein (age 73), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:29 UTC.
| President, CEO & Director | J. J. Finkelstein (age 73) |
|---|---|
| Founder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board | Allan L. Goldstein (age 87) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MYMX | MYMETICS CORPORATION | USD 0 | ▲ 0% |
| GTHP | Guided Therapeutics, Inc. | USD 0.2 | ▲ 0% |
| PKTX | ProtoKinetix, Inc. | USD 0.01 | ▼ 6.14% |
| PVCT | Provectus Biopharmaceuticals, I | USD 0.07 | ▲ 6.35% |
| BICX | BioCorRx Inc. | USD 0.4 | ▲ 5.82% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:29 UTC. This page is informational and not investment advice.